Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSenic Puts Phase IIb ALLOB Trial on Hold
Details : ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spin...
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 19, 2023
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spin...
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : ABO Securities
Deal Size : $5.4 million
Deal Type : Financing
Bone Therapeutics Secures EUR 5 Million Financing
Details : The proceeds of the financing will be used to advance the clinical development of Bone Therapeutics’ lead asset, the allogeneic bone cell therapy, ALLOB.
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 04, 2022
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : ABO Securities
Deal Size : $5.4 million
Deal Type : Financing
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALLOB (allogeneic bone cell therapy) represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells.
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 15, 2022
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Pregene
Deal Size : $53.6 million
Deal Type : Termination
Bone Therapeutics to Regain Worldwide Rights to ALLOB
Details : ALLOB (allogeneic bone cell therapy) is an allogeneic osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells. It represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells into bo...
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : $9.7 million
July 10, 2022
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Pregene
Deal Size : $53.6 million
Deal Type : Termination
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : ABO Securities
Deal Size : $5.4 million
Deal Type : Agreement
Details : The proceeds of the financing will contribute to continuing to advance the clinical development of Bone Therapeutics’ lead asset, its allogeneic bone cell therapy, ALLOB.
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 31, 2022
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : ABO Securities
Deal Size : $5.4 million
Deal Type : Agreement
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bone Therapeutics Treats First Patient in ALLOB Phase IIb Tibial Fracture Study
Details : The ALLOB Tibial Fracture Phase IIb study is a randomized, double-blind, placebo-controlled study. In this study, the potential of ALLOB to accelerate fracture healing and prevent late-stage complications in patients with difficult fractures in the shinb...
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $3.7 million
Deal Type : Private Placement
Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement
Details : The gross proceeds will be used to advance Bone Therapeutics’ lead orthopedic asset, ALLOB, through mid-stage clinical development and will also support the acceleration of the development of the new iMSC cell and gene therapy platform.
Product Name : Allob
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2021
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $3.7 million
Deal Type : Private Placement
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Catalent has purchased the shares of SCTS and a purpose-built CGxP facility of approximately 41,000 square-foot. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy ...
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 16, 2020
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : $14.2 million
Deal Type : Acquisition
Details : Agreements will streamline and economize the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus on the development of products from its differentiated MSC platform of cell an...
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 30, 2020
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : $14.2 million
Deal Type : Acquisition